Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

psychiatric diseases

- PMLiVE

Germany’s coronavirus infections climb but deaths remain low

Experts debate ‘anomaly’ as other countries record higher death rates

- PMLiVE

FDA clears wider use for Boehringer’s Ofev in lung disease

Drug was first approved in 2014 for pulmonary fibrosis

- PMLiVE

Boehringer links up with Trutino for cancer R&D

Collaboration agreement will focus on cytokine treatments

- PMLiVE

Boehringer bolsters NASH pipeline with Enleofen link-up

Agrees to pay up to €1bn for each new marketed product

- PMLiVE

Boehringer Ingelheim to manufacture first biologic in China under new reforms

German pharma will manufacture BeiGene's PD-1 inhibitor

- PMLiVE

FDA advisors say no to empagliflozin in type 1 diabetes

Approval of Boehringer, Lilly-partnered drug expansion looks unlikely

- PMLiVE

Amgen exits neuroscience R&D to focus on growth areas

Move has resulted in loss of around 180 jobs

german flag

German pharma experiencing a ‘Brexit boost’

Opinion poll ranked Germany as top pharma market in EU

- PMLiVE

Eli Lilly shutters UK neuroscience unit, with 80 job losses expected

Company says decision is not related to Brexit

- PMLiVE

Boehringer bags FDA OK for Ofev in rare lung disease ILD

First drug approved for condition

- PMLiVE

Boehringer bolsters KRAS push with $720m Lupin deal

Signs of progress in the field are emerging

- PMLiVE

Boehringer Ingelheim forms ‘virtual research’ alliance with MD Anderson

Will focus on developing cancer therapies

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links